12 patents
Utility
Cholix-derived carriers for oral delivery of heterologous payload
22 Nov 22
The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal).
Thomas Carl Hunter, Randall J. Mrsny, Weijun Feng, Tahir Mahmood, Charles Olson, Sally Postlethwaite
Filed: 21 Dec 20
Utility
Compositions, formulations and interleukin production and purification
25 Oct 22
Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered.
Derek Maclean, Randall J. Mrsny, Kevin Yin, Tahir Mahmood, Bittoo Kanwar, Sally Postlethwaite, Weijun Feng, Sean Dalziel, Hyojin Kim, Rajendra Tandale, Marvin Garovoy, John Koleng
Filed: 27 Oct 21
Utility
Compositions, formulations and interleukin production and purification
11 Oct 22
Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered.
Randall J. Mrsny, Tahir Mahmood, Amir Porat, Charles Olson, Sally Postlethwaite, Weijun Feng, Khushdeep Mangat
Filed: 17 Nov 21
Utility
Toxin-derived delivery constructs for pulmonary delivery
30 Aug 22
The present disclosure relates to isolated non-naturally occurring delivery constructs comprising a bacterial toxin-derived delivery construct coupled to a biologically active therapeutic cargo; wherein the delivery construct is capable of delivering the biologically active cargo via transcytosis transport across an epithelial cell; and wherein the delivery construct does not comprise a bacterial toxin-derived translocation domain or a bacterial toxin-derived catalytic (cytotoxic) domain.
Keyi Liu, Julia Dawn Mackay, Weijun Feng, Thomas Carl Hunter, Randall J. Mrsny
Filed: 8 Sep 20
Utility
Cholix-derived carriers for oral delivery of heterologous payload
10 May 22
The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal).
Randall J. Mrsny, Charles Olson, Sally Postlethwaite, Thomas Carl Hunter, Tahir Mahmood, Weijun Feng
Filed: 27 May 20
Utility
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
15 Feb 22
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
Randall J. Mrsny, Tahir Mahmood
Filed: 27 Aug 20
Utility
Compositions, formulations and interleukin production and purification
4 Jan 22
Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered.
Randall J. Mrsny, Tahir Mahmood, Amir Porat, Charles Olson, Sally Postlethwaite, Weijun Feng, Khushdeep Mangat
Filed: 5 Feb 21
Utility
Compositions, formulations and interleukin production and purification
2 Nov 21
Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered.
Derek Maclean, Randall J. Mrsny, Kevin Yin, Tahir Mahmood, Bittoo Kanwar, Sally Postlethwaite, Weijun Feng, Sean Dalziel, Hyojin Kim, Rajendra Tandale, Marvin Garovoy, John Koleng
Filed: 5 Feb 21
Utility
Delivery constructs for transcytosis and related methods
8 Jun 21
The present disclosure provides non-naturally occurring fusion molecules comprising therapeutic cargo moieties, such as IL-22 with a carrier.
Randall J. Mrsny, Tahir Mahmood, Charles Olson, Weijun Feng, Sally Postlethwaite
Filed: 15 Jun 20
Utility
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
12 Oct 20
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
Randall J. Mrsny, Tahir Mahmood
Filed: 3 Oct 18
Utility
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
28 Sep 20
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
Randall J. Mrsny, Tahir Mahmood
Filed: 2 Dec 18
Utility
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
28 Sep 20
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
Randall J. Mrsny, Tahir Mahmood
Filed: 13 Dec 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first